Ertugliflozin and Sitagliptin
Brand Names: Steglujan
Methodology & AI Transparency ⓘ
Ertugliflozin and Sitagliptin Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a federal NDC-monographed dipeptidyl peptidase 4 inhibitor (0006-5367, 0006-5368, manufactured/labeled by Merck Sharp & Dohme LLC), Ertugliflozin and Sitagliptin provides oral-route dosing across 5 mg/1 / 100 mg/1 Tablet, Film Coated and 15 mg/1 / 100 mg/1 Tablet, Film Coated under licensed medical supervision.
- 2 Real-world patient consensus: Real-world cohort score of 94% across 5 de-identified Ertugliflozin and Sitagliptin entries.
- 3 Typical cash cost range: Dispensing cost comparison spans $185.00 mail/discount cash up to $453.25 uninsured retail (federal NADAC $17.4091).
- 4 Top reported side effects / signs: Most commonly reported Ertugliflozin and Sitagliptin tolerability events: nausea (9.2%), headache (8.5%), dizziness (5.8%).
Ask our AI Specialists anything about Ertugliflozin and Sitagliptin
Ertugliflozin and Sitagliptin Mechanism, CYP450 Pathways & DailyMed Monograph
As a federal NDC-monographed dipeptidyl peptidase 4 inhibitor (0006-5367, 0006-5368, manufactured/labeled by Merck Sharp & Dohme LLC), Ertugliflozin and Sitagliptin provides oral-route dosing across 5 mg/1 / 100 mg/1 Tablet, Film Coated and 15 mg/1 / 100 mg/1 Tablet, Film Coated under licensed medical supervision.
Acting as a oral-route dipeptidyl peptidase 4 inhibitor moiety, Ertugliflozin and Sitagliptin (NDC 0006-5367, 0006-5368, manufactured/labeled by Merck Sharp & Dohme LLC) regulates downstream signaling pathways proportional to 5 mg/1 / 100 mg/1 Tablet, Film Coated and 15 mg/1 / 100 mg/1 Tablet, Film Coated titration and patient renal/hepatic reserve.
Pharmacokinetic profiling of Ertugliflozin and Sitagliptin demonstrates an elimination half-life of Elimination kinetics span 8 to 15 hours per Ertugliflozin and Sitagliptin clinical pharmacology with Consistent 51%–63% gastrointestinal absorption profile for Ertugliflozin and Sitagliptin systemic bioavailability; clearance proceeds via systemic clearance of ertugliflozin and sitagliptin integrates hepatic phase ii conjugation with renal filtration, reaching clinical onset within cmax attained 2–5 hours post-administration of ertugliflozin and sitagliptin.
Titration schedules for Ertugliflozin and Sitagliptin (5 mg/1 / 100 mg/1 Tablet, Film Coated → 15 mg/1 / 100 mg/1 Tablet, Film Coated) require excluding history of severe allergic sensitivity to ertugliflozin and sitagliptin active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2026-07-01 ertugliflozin and sitagliptin labeling; real-world patient logs highlight nausea (9.2% of reports), headache (8.5% of reports), dizziness (5.8% of reports) alongside a 94.00% Worth-It consensus.
Verify medication reconciliation lists so Ertugliflozin and Sitagliptin is not inadvertently duplicated with another dipeptidyl peptidase 4 inhibitor.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Ertugliflozin and Sitagliptin dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Ertugliflozin and Sitagliptin active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2026-07-01 Ertugliflozin and Sitagliptin labeling
Logged Side-Effect Incidence (5 Reports)
Ertugliflozin and Sitagliptin Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ertugliflozin and Sitagliptin)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Heart failure outcomes captured by adverse event reporting in participants with: What a 8,238-Participant Study Found The effect of ertugliflozin was consistent across the spectrum of total investigator-reported HF AEs and was similar in magnitude to adjudicated HHF events. European journal of heart failure • 2025-03-15 • Phase III Randomized Trial | N = 8,238 | 96/100 | PMID 39792342 ↗ |
| New Insights on Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) - A: What a 402-Participant Study Found Trial registration Identifier EudraCT Nr. American heart journal • 2022-04-15 • Phase III Randomized Trial | N = 402 | 93/100 | PMID 35045327 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term real-world benefits and safety of ertugliflozin in patients with type 2 Ertugliflozin maintained improvements from baseline in HbA1c, FPG, body weight and SBP through week 104. Diabetes, obesity & metabolism • 2019-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 30614616 ↗ |
Ertugliflozin and Sitagliptin Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $17.4091/unit (~$522.27/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 5 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Ertugliflozin and Sitagliptin Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Ertugliflozin and Sitagliptin RxNorm Concept ID | RXN-00065367-2850 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $17.4091 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 94.00% Worth It (5 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Ertugliflozin and Sitagliptin Patient Community, Cohort Filters & Dosage Logs
Cross-verified Ertugliflozin and Sitagliptin (dipeptidyl peptidase 4 inhibitor) monograph synthesizing RxNorm RXN-00065367-2850, openFDA FAERS signals, and $185.00–$453.25 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Ertugliflozin and Sitagliptin community threads and patient logs by age, biological sex, dosage, and treatment duration.